TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Mucormycosis
New findings reported from Complutense University describe advances in mucormycosis
May 5th, 2009
"Although mucormycosis is not as frequent as candidiasis and aspergillosis, it remains a challenge for clinicians and microbiologists," scientists in Madrid, Spain report. "Mucormycosis is a rare infection, although some institutions report an increasing incidence, and it continues to have a high mortality rate despite antifungal treatment. Few antifungal agents have in vitro activity against the Mucorales," wrote J. Guinea and colleagues, Complutense University. The researchers concluded: "Amphotericin B remains the drug of choice and posaconazole is a promising alternative." Guinea and colleagues published their study in...
Source: TB & Outbreaks Week (2009-05-05)
|
